NLRP3 and metabolic syndrome: New anti-inflammatory compounds, such as NLR family pyrin domain containing 3 (NLRP3) inflammasome inhibitors–1,3,4-oxadiazol-2-one derivative 5 (INF200), have shown notable improvements in glucose tolerance and systemic inflammation in preclinical models of diet-induced metabolic syndrome.